With gains of 2.2%, Lantheus was one of the winners on Wall Street today. Its shares are now trading at $84.89 and have logged a -1.0% daily outperformance of the S&P 500. Don't join the feeding frenzy before checking some basic facts about this stock:
-
Lantheus has moved 41.5% over the last year, and the S&P 500 logged a change of -7.0%
-
LNTH has an average analyst rating of buy and is -21.67% away from its mean target price of $108.38 per share
-
Its trailing earnings per share (EPS) is $0.41
-
Lantheus has a trailing 12 month Price to Earnings (P/E) ratio of 207.1 while the S&P 500 average is 15.97
-
Its forward earnings per share (EPS) is $5.55 and its forward P/E ratio is 15.3
-
The company has a Price to Book (P/B) ratio of 12.8 in contrast to the S&P 500's average ratio of 2.95
-
Lantheus is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
-
The company has a free cash flow of $-138,542,752.00, which refers to the total sum of all its inflows and outflows of cash over the last quarter
-
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.